Nephrotic Syndrome Market was valued at USD 1.65 billion in 2024 and is expected to reach USD 2.75 billion by 2034

Market Overview
The Nephrotic Syndrome Market was valued at USD 1.65 billion in 2024 and is expected to reach USD 2.75 billion by 2034, expanding at a CAGR of 5.6% during the forecast period.

Growth is primarily driven by rising global cases of chronic kidney disease (CKD), diabetes, lupus nephritis, and genetic kidney disorders. Increasing use of biologics, advancements in diagnostics, and stronger investment in kidney research continue to enhance market expansion.

Nephrotic syndrome-characterized by heavy proteinuria, hypoalbuminemia, edema, and lipid abnormalities-remains a major global health burden. Improved nephrology infrastructure and wider clinical adoption of targeted therapies are further propelling market growth.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72000

Market Dynamics
Drivers
• Surging global CKD incidence, affecting over 850 million people worldwide.
• Rising prevalence of diabetes and lupus nephritis, significantly contributing to secondary nephrotic syndrome cases.
• Growing shift toward targeted biologics such as rituximab and emerging podocyte-modulating agents.
• Improved screening methods and biomarker-based diagnosis increasing early detection.
• Expansion of pediatric nephrology programs and awareness campaigns.

Restraints
• High cost of biologics, often ranging between USD 20,000-40,000 annually.
• Recurrence and relapse challenges associated with long-term steroid therapy.
• Limited early detection in lower-income regions due to diagnostic gaps.

Opportunities

• Development of next-generation biologics and steroid-sparing therapies for resistant nephrotic syndrome.
• Use of AI and predictive biomarkers for early identification and relapse prediction.
• Growth of nephrology centers and research collaborations in Asia-Pacific and Latin America.
• Increasing emphasis on real-world evidence studies to optimize treatment pathways.

Market Growth Outlook (2024-2034)
The market grows from USD 1.65 billion in 2024 to USD 2.75 billion in 2034, representing a 5.6% CAGR. Continued rise in FSGS, membranous nephropathy, and diabetes-related kidney damage remains the core growth engine. The strong therapeutic pipeline and emerging biologics are expected to reshape treatment standards over the next decade.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/72000/nephrotic-syndrome-market

Segmentation Analysis
By Type
Primary nephrotic syndrome-including minimal change disease, focal segmental glomerulosclerosis (FSGS), and membranous nephropathy-accounts for more than half of total market revenue due to higher global incidence.
Secondary nephrotic syndrome, primarily caused by diabetes, lupus, infections, and drug-induced kidney damage, is the fastest-growing segment, supported by rising metabolic disorders worldwide.

By Treatment
Corticosteroids remain the most widely used first-line therapy, contributing the largest revenue share.
Immunosuppressants such as cyclosporine, tacrolimus, and cyclophosphamide continue to play a key role in relapse management.
Biologic therapies represent the fastest-growing treatment category, expanding at over 7% CAGR, driven by increasing adoption of rituximab and pipeline agents targeting podocyte injury.
Supportive treatments such as ACE inhibitors, ARBs, diuretics, and statins remain essential components of disease management.

By Diagnosis
Urinalysis is the dominant diagnostic method due to wide availability and cost-effectiveness.
Advanced testing-including renal function blood tests, lipid profiling, and biomarkers-supports improved clinical accuracy.
Renal biopsy remains the gold standard for identifying minimal change disease, FSGS, and membranous nephropathy.
Ultrasound and CT imaging help assess kidney structure and rule out other renal abnormalities.

By End User
Hospitals account for the majority of market share due to the need for specialized nephrology care.
Nephrology clinics and ambulatory centers are growing steadily as outpatient management becomes more common.
Research institutes are increasingly involved in developing biomarkers, targeted biologics, and gene-level therapies.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72000

Regional Insights

North America
North America leads the global market with approximately 38% share, driven by high CKD prevalence, strong reimbursement mechanisms, early use of biologics, and ongoing clinical trials. The regional market was valued at about USD 630 million in 2024.

Europe
Europe remains a major market with a well-established nephrology ecosystem. Strong government support for kidney disease management, along with availability of advanced biologics, fuels steady growth.

Asia Pacific
Asia Pacific is the fastest-growing region, expanding at an estimated 7.1% CAGR. Rising diabetes rates, growing pediatric kidney disorders, and expanding nephrology infrastructure in countries like India, China, and Japan fuel long-term market acceleration.

Latin America & Middle East/Africa
These regions show moderate but consistent growth supported by improved healthcare access, growing CKD awareness, and expanding kidney care programs-although cost barriers remain significant.

Competitive Landscape
The competitive landscape is characterized by companies focusing on immunotherapies, podocyte-targeting drugs, steroid-sparing regimens, and clinical programs for FSGS and membranous nephropathy.
Key Companies Include:
Pfizer, Novartis, GlaxoSmithKline, Roche, AbbVie, Bristol Myers Squibb, Bayer, Takeda, Omeros Corporation, and Travere Therapeutics.
These companies are investing heavily in developing biologics, improving long-term kidney outcomes, and strengthening global distribution through strategic collaborations.

Recent Developments
• New drug candidates targeting podocyte repair show promising results in Phase II and Phase III trials.
• Increased adoption of rituximab for steroid-resistant and frequently relapsing nephrotic syndrome.
• Regulatory agencies advancing approvals for rare kidney disease treatments.
• Collaborative research initiatives improving biomarker discovery and disease monitoring.

This report is also available in the following languages : Japanese (ネフローゼ症候群市場), Korean (신증후군 시장), Chinese (肾病综合征市场), French (Marché du syndrome néphrotique), German (Markt für nephrotisches Syndrom), and Italian (Mercato della sindrome nefrosica), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72000

Our More Reports:

Diabetic Peripheral Neuropathy Market
https://exactitudeconsultancy.com/reports/71902/diabetic-peripheral-neuropathy-market

Fibromyalgia Market
https://exactitudeconsultancy.com/reports/71904/fibromyalgia-market

Hypothalamic Obesity Market
https://exactitudeconsultancy.com/reports/71906/hypothalamic-obesity-market

Leigh Syndrome Market
https://exactitudeconsultancy.com/reports/71908/leigh-syndrome-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.